Originally published by our sister publication Infectious Disease Special Edition
By Heidi Splete
Five-year follow-up data from the triple combination HIV therapy bictegravir-emtricitabine-tenofavir alafenamide (B/F/TAF) showed high rates of disease suppression and patient tolerance in adults older than 50 years, based on data from two studies presented at IDWeek 2024, held recently in Los Angeles.
The number of individuals with HIV-1 who are older than 50 years is rising, but long-term